Pyoderma gangrenosum is a rare, painful skin condition where the immune system causes rapidly expanding ulcers, most often on the legs. Despite its name, it has nothing to do with gangrene or infection. It’s an inflammatory disorder driven by an overactive immune response, and roughly one in three people who develop it have an underlying condition like inflammatory bowel disease or rheumatoid arthritis.
How It Starts and What It Looks Like
The classic form begins as a small pustule or tender bump that quickly breaks down into an open wound. Within days, that wound can expand into a deep, painful ulcer with a distinctive purple-red border. The edges of the ulcer are irregular and undermined, meaning the wound tunnels beneath the surrounding skin. This rapid progression from a minor-looking spot to a significant ulcer is one of the hallmarks that distinguishes pyoderma gangrenosum from other skin conditions.
Not every case looks the same. There are several recognized variants:
- Classic (ulcerative): The most common type, featuring deep, painful ulcers with purple, undermined borders. These typically appear on the shins or lower legs.
- Bullous: Characterized by fluid-filled blisters rather than deep ulcers, usually appearing on the arms or face. This form overlaps with another inflammatory skin condition called Sweet syndrome.
- Pustular: Multiple small pustules that may resolve on their own or progress into ulcers. This variant is closely tied to inflammatory bowel disease.
- Vegetative: The mildest form, with more superficial, slower-growing wounds that are less painful than the classic type.
Why It Happens
Pyoderma gangrenosum is a neutrophilic dermatosis, which means it’s caused by a specific type of white blood cell (neutrophils) flooding into the skin and causing tissue destruction. Normally, neutrophils fight infection. In pyoderma gangrenosum, they’re recruited to the skin without any infection present and release destructive enzymes that break down healthy tissue. Inflammatory signaling molecules, particularly tumor necrosis factor (TNF), play a central role in driving this process, which is why medications that block TNF can be effective treatments.
One of the most frustrating features is a phenomenon called pathergy: the wounds can worsen in response to trauma. A needle stick, a surgical incision, or even minor bumps to the skin can trigger new ulcers or cause existing ones to expand. This makes the condition especially tricky, because the instinct to surgically clean a worsening wound can actually make things worse. Research confirms that aggressive surgical removal of inflamed tissue during an active flare can cause deterioration, though gentle removal of dead tissue does not appear to carry the same risk.
Conditions Linked to Pyoderma Gangrenosum
About 33% of people with pyoderma gangrenosum have an associated systemic disease. A large UK study found that inflammatory bowel disease (Crohn’s disease or ulcerative colitis) was present in 20% of cases, rheumatoid arthritis in about 12%, and blood disorders in roughly 4%. This means if you’re diagnosed with pyoderma gangrenosum and haven’t been evaluated for these conditions, your doctor will likely want to run additional tests.
The remaining two-thirds of cases occur without any identifiable underlying disease. Having an associated condition doesn’t necessarily mean treating that condition will resolve the skin ulcers, though in some cases, controlling bowel inflammation, for example, does help the skin improve.
How It’s Diagnosed
There is no single blood test or biopsy finding that confirms pyoderma gangrenosum. Diagnosis relies on recognizing the clinical pattern and ruling out other causes of skin ulceration, including infection, blood vessel disease, and cancer. A skin biopsy is usually performed not to confirm pyoderma gangrenosum directly but to exclude other conditions. Under the microscope, the tissue typically shows dense collections of neutrophils without evidence of infection.
Dermatologists sometimes use a scoring system called the PARACELSUS score to support the diagnosis. Points are assigned based on features like progressive wound growth, a reddish-violet wound border, extreme pain (rated above 4 out of 10), an irregular or bizarre ulcer shape, wound development at a site of prior trauma, improvement with immune-suppressing medications, and the presence of an associated systemic disease. A combined score of 10 or more makes the diagnosis highly probable. The system helps because pyoderma gangrenosum is frequently misdiagnosed, and incorrect treatment (especially unnecessary surgery) can cause significant harm.
Treatment and What to Expect
Because the problem is an overactive immune response, treatment centers on calming inflammation. For smaller or milder ulcers, topical therapy applied directly to the wound can be effective, with a median healing time of about 45 days in one observational study. More extensive or rapidly progressing disease typically requires systemic medication. In clinical trials, patients on systemic immune-suppressing therapy took a median of 112 to 134 days to achieve wound closure, depending on the specific drug used.
For cases that don’t respond to standard immune-suppressing medications, biologic therapies that target TNF have shown meaningful results. In a randomized controlled trial, 69% of patients treated with a TNF-blocking biologic showed clinical improvement. Timing matters significantly: patients whose disease had been present for less than 12 weeks responded at rates above 90%, while those with ulcers lasting longer than three months responded less than half the time. Early, aggressive treatment of the immune dysfunction gives the best chance of healing.
Pain management is also a central part of care. The ulcers are often intensely painful, well beyond what their appearance might suggest, and adequate pain control can make a real difference in quality of life during the weeks or months it takes for wounds to close.
Recurrence and Long-Term Outlook
Pyoderma gangrenosum is not a one-and-done condition for everyone. Recurrence rates in clinical studies range from about 15% for those treated with topical therapy to roughly 28 to 30% for those who needed systemic treatment. The higher recurrence rate in the systemic group likely reflects more severe disease rather than a failing of the medication itself.
Healed ulcers often leave behind significant scarring, sometimes described as a cribriform (sieve-like) pattern. The scars can be disfiguring, particularly on the legs, and some people pursue scar management once the active disease is controlled. Because recurrence is possible over months or even years, staying aware of early signs (a new painful bump, a wound that isn’t healing as expected) allows for prompt treatment before the ulcer has a chance to expand.